When combined, these results show for the first time a functional interdependence between Dot1L and menin in estrogen-sensitive and AE-resistant breast cancer, and point to BAZ1B as a member of a Dot1L-menin regulatory network exploitable for devising new ways to treat endocrine-resistant BC. This evidence concerns the gene MEN1 and breast carcinoma.